Plasmodium falciparum glutamate-rich protein (GLURP)

Plasmodium falciparum glutamate-rich protein (GLURP, also referred to as PfGARP in recent literature) is a parasite-encoded cell surface antigen highly expressed on the surface of infected erythrocytes, particularly during the trophozoite and schizont stages of the intraerythrocytic cycle[1][4][5]. The protein contains extensive glutamic acid-rich and lysine-rich repetitive domains as well as highly immunogenic, antigenic regions[1][2]. GLURP/PfGARP binds to erythrocyte band 3 and participates in the cytoadherence and possibly immune evasion strategies of the parasite[1][4][5]. Antibodies against GLURP are present in individuals exposed to malaria and have been associated with clinical protection; such antibodies contribute to parasite growth inhibition via antibody-dependent cellular inhibition involving monocytes, but do not directly affect parasite invasion[2][6][7]. Due to its strong immunogenicity and surface exposure, GLURP/PfGARP is being considered as a candidate for malaria vaccine development, as well as a potential biomarker for previous exposure and immunity to malaria[4][6]. No approved drugs directly target GLURP/PfGARP, but it remains an important experimental and therapeutic target in the context of malaria vaccine design.

Other names

GLURP (Glutamate-rich protein)PfGARP (Plasmodium falciparum glutamic acid-rich protein)Plasmodium falciparum glutamic acid-rich proteinPF3D7_0113000 (gene ID for PfGARP)

Target of antibody-dependent cellular inhibition (ADCI) by human IgG. Possible target for vaccine-induced humoral immune responses. Polyvalent antibody-mediated growth inhibition in vitro. Putative therapeutic target for vaccine development.